Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.54 |
| ▸ | CFD | P00746 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | F11 | P03951 | 1/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757878 | 1.00 | HTR1A (0.57) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL1412911 | 0.88 | HTR1A (0.59) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL10583993 | 0.88 | FABP4 (0.60) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| Methane SCHEMBL22289610 | 0.87 | HTR1A (0.57) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL31757965 | 0.86 | CFD (0.68) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL1007508 | 0.86 | CFD (0.68) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL68571 | 0.83 | L3MBTL1 (0.69) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL9840655 | 0.83 | L3MBTL1 (0.49) | PTGER1L3MBTL1HPGDALDH1A1LMNA | |
| SCHEMBL8324677 | 0.82 | L3MBTL1 (0.64) | HTR1ADRD2PTGER1PTGER4PTGER3 | |
| SCHEMBL2988197 | 0.81 | L3MBTL1 (0.56) | HTR1ADRD2PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| US-8580783-B2 | [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120184546-A1 | [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2012-07-19 | — | — | US | disclosed |
| EP-2475665-A1 | [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029775-A1 | [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-03-17 | — | — | WO | disclosed |
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| WO-2002024653-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-1163225-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055137-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-5661187-A | ADMINISTERING TO TREAT AN ALLERGIC OR INFLAMMATORY CONDITION; SIDE EFFECT REDUCTION | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-08-26 | — | — | US | disclosed |
| US-5462567-A | Antideposit agents | CHEVRON CHEMICAL COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0664780-A1 | 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | HSP90AB1, HSP90AA1, HSP90AB2P | HTR1A 1044/4885DRD2 4366/4885PTGER1 2088/4885 |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | HTR1A 1601/4885DRD2 4476/4885PTGER1 494/4885 |
| US-20120184546-A1 | [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | HSP90AB1, HSP90AA1, HSP90AB2P | HTR1A 959/4885DRD2 4490/4885PTGER1 1380/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | HTR1A 1478/4885DRD2 4522/4885PTGER1 395/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | HTR1A 1560/4885DRD2 4562/4885PTGER1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.